Cargando…

Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial

OBJECTIVES: The NAnoliPOsomaL Irinotecan (NAPOLI-1) study (NCT01494506) was the largest global phase 3 study in a post-gemcitabine metastatic pancreatic adenocarcinoma (mPAC) population (N = 417). The subanalyses reported here investigated the prognostic effect of tumor characteristics and disease s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macarulla Mercadé, Teresa, Chen, Li-Tzong, Li, Chung-Pin, Siveke, Jens T., Cunningham, David, Bodoky, György, Blanc, Jean-Frédéric, Lee, Kyung-Hun, Dean, Andrew, Belanger, Bruce, Wang-Gillam, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946097/ https://www.ncbi.nlm.nih.gov/pubmed/31856081 http://dx.doi.org/10.1097/MPA.0000000000001455

Ejemplares similares

Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study
por: Bang, Yung‐Jue, et al.
Publicado: (2019)

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
por: Chen, Li-Tzong, et al.
Publicado: (2019)

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis
por: Pelzer, Uwe, et al.
Publicado: (2017)

A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
por: Kikuchi, Koji, et al.
Publicado: (2022)

Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line
por: Akhoundova Sanoyan, Dilara, et al.
Publicado: (2020)

Napoli milionaria! /
por: De Filippo, Eduardo, 1900-1984
Publicado: (1979)

A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
por: Bathe, Oliver F, et al.
Publicado: (2009)

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma
por: Singhal, Ruchi, et al.
Publicado: (2023)

Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis
por: Chen, Ke, et al.
Publicado: (2016)

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients
por: Mabro, M, et al.
Publicado: (2006)

nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
por: Ueno, Makoto, et al.
Publicado: (2020)

Napoli esoterica : un itinerario nei misteri napoletani /
por: Buonoconto, Mario
Publicado: (1999)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
por: Adiwijaya, BS, et al.
Publicado: (2017)

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial
por: Skof, Erik, et al.
Publicado: (2009)

Lezioni all'universita di Napoli
por: Majorana, Ettore
Publicado: (1987)

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer
por: Brendel, Karl, et al.
Publicado: (2021)

Napoli testa di ponte del Grid Computing
Publicado: (2008)

Real Orto Botanico di Napoli : CLXIV disegni botanici dell'ottocento napoletano /
Publicado: (2010)

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
por: Barbier, Sandrine, et al.
Publicado: (2023)

The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
por: Su, Yung-Yeh, et al.
Publicado: (2020)

Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy
por: Carter, Kevin A, et al.
Publicado: (2016)

Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
por: Frampton, James E.
Publicado: (2020)

Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs
por: Milano, Gérard, et al.
Publicado: (2022)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023)

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
por: Gupta, Amol, et al.
Publicado: (2023)

Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model
por: Huang, Jiao-Ren, et al.
Publicado: (2019)

Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
por: Frampton, James E.
Publicado: (2020)

Single-treatment tumor ablation with photodynamic liposomal irinotecan sucrosulfate
por: Ghosh, Sanjana, et al.
Publicado: (2022)

The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017
por: Ascierto, Paolo A., et al.
Publicado: (2018)

Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
por: Su, Yung-Yeh, et al.
Publicado: (2020)

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
por: Sachdev, Jasgit C., et al.
Publicado: (2020)

Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer
por: Su, Yung-Yeh, et al.
Publicado: (2023)

Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives
por: Woo, Wonhee, et al.
Publicado: (2019)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
por: Cassidy, J, et al.
Publicado: (2006)

Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens
por: Chaigneau, Thomas, et al.
Publicado: (2023)

Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
por: Saunders, M P, et al.
Publicado: (2004)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data
por: Buhl, Ida Kappel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cjk72prc78ogmq7ugtmu1m0uio